News

Public · Published

Canaccord Genuity maintains Madrigal Pharmaceuticals at Buy, raises price target to $633 from $612

Canaccord Genuity kept its Buy rating on Madrigal Pharmaceuticals and raised its price target to $633 from $612, a 3.4% increase. The new target implies 58.1% upside from the November 4 closing price of $400.43.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Madrigal Pharmaceuticals and raised its price target to $633 from $612, a 3.4% increase. The new target implies 58.1% upside from the November 4 closing price of $400.43.

Confirmed

Global impact / market context

The higher target signals that Canaccord sees more potential value in Madrigal shares, while leaving its Buy rating unchanged. If investors act on that view, increased demand could support the share price, but the target is an analyst estimate, not a guaranteed outcome.

Analyst inference

The update changes one analyst’s stated price target, not Madrigal’s reported business results or financial outlook. Its 58.1% implied upside is calculated against the November 4 close, so it depends on that reference price and does not establish future returns.

Analyst inference

What to watch

  1. Whether Canaccord publishes further changes to its Buy rating or $633 target, which would show whether this revised view is maintained or adjusted. Analyst inference
  2. Whether Madrigal reports company or financial developments in later updates; none are described in this article, and such news could change the basis for analysts’ estimates. Analyst inference
  3. How Madrigal’s share price compares with the $633 target over time; the stated 58.1% upside uses the November 4 close of $400.43. Analyst inference

Evidence

  • Original source link unavailable